drugset / Trial / NCT01253499

Multiple Dose Study of TRx0037

NCT01253499 ↗

Phase 1 Completed 31 enrolled TauRx Therapeutics Ltd Quotient Clinical · collab
RandomizedSingle-groupTriple-blindBasic science

Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of TRx0037 after multiple doses in elderly volunteers.

Timeline

Start
2010-03
Primary completion
2010-05
Completion
2010-05

Drugs

EvaluationDrugModalityDoseRoute
Subject TRx0037 Unknown 100 mg —
Subject TRx0037 Unknown 175 mg —

Indications